Ikena Oncology Inc.

NASDAQ: IKNA · Real-Time Price · USD
17.16
15.79 (1152.55%)
At close: Jul 25, 2025, 3:59 PM

Company Description

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs.

Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway.

It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer.

The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ikena Oncology Inc.
Ikena Oncology Inc. logo
Country United States
IPO Date Mar 26, 2021
Industry Biotechnology
Sector Healthcare
Employees 10
CEO Mark Manfredi

Contact Details

Address:
645 Summer Street
Boston, Massachusetts
United States
Website https://ikenaoncology.com

Stock Details

Ticker Symbol IKNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001835579
CUSIP Number 45175G108
ISIN Number US45175G1085
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Dr. Mark Manfredi Ph.D. President, Chief Executive Officer & Director
Dr. Jotin Marango M.D., Ph.D. Chief Operating Officer, Chief Financial Officer, Head of Corporate Development & Treasurer
Bob Lally Senior Vice President of Finance & Operations
David Damphousse M.S. Senior Vice President of Clinical Development Operations
Jeffrey Ecsedy Ph.D. Chief Development Officer
Rebecca Cohen Senior Vice President of Investor Relations, Corporate Strategy & Communication

Latest SEC Filings

Date Type Title
Aug 12, 2025 8-K/A [Amend] Current Report
Aug 07, 2025 4 Filing
Aug 07, 2025 3 Filing
Aug 05, 2025 8-K Current Report
Aug 04, 2025 SCHEDULE 13G Filing
Aug 04, 2025 SCHEDULE 13G/A [Amend] Filing
Aug 01, 2025 8-K Current Report
Jul 30, 2025 4 Filing
Jul 30, 2025 4 Filing
Jul 30, 2025 SCHEDULE 13D/A [Amend] Filing